R&D | January 13, 2026
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The expansion includes a larger technical and service team and increased local procurement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Subscribe To Our Newsletter & Stay Updated
